Parkside Financial Bank & Trust Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Parkside Financial Bank & Trust cut its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,979 shares of the company’s stock after selling 684 shares during the period. Johnson & Johnson accounts for about 0.9% of Parkside Financial Bank & Trust’s holdings, making the stock its 22nd biggest position. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,774,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its holdings in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. lifted its holdings in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares during the period. Finally, USS Investment Management Ltd lifted its holdings in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3 %

Johnson & Johnson stock opened at $168.31 on Tuesday. The stock has a market cap of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The stock has a 50-day moving average price of $176.07 and a 200 day moving average price of $171.13. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Bank of America reduced their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Morgan Stanley reduced their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Finally, SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at approximately $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.